Anti-HGFR/c-Met Antibody (Emibetuzumab)
Catalog No.
F2060
Anti-HGFR/c-Met Antibody (Emibetuzumab)
Featured Products
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab has high neutralization and internalization activity, and can effectively inhibit the activation of HGF-dependent and independent MET pathways and tumor growth. Emibetuzumab can be used in cancer research.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
144.56 kDa
Dry ice
1365287-97-3
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
LY2875358
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P08581
Human
Unconjugated
Monoclonal
Protein A
IgG4SP
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human c MET His at 2 ug/mL can bind Anti-HGFR/c-Met Antibody (Emibetuzumab)
HGFR / c-Met
Please avoid freeze-thaw cycles.